Could implementation of mifepristone address Canada's urban-rural abortion access disparity: a mixed-methods implementation study protocol.
Abortifacient Agents, Steroidal
/ therapeutic use
Abortion, Induced
/ methods
Adult
Canada
Female
Health Services Accessibility
/ statistics & numerical data
Healthcare Disparities
/ statistics & numerical data
Humans
Mifepristone
/ therapeutic use
Pregnancy
Prospective Studies
Qualitative Research
Rural Population
/ statistics & numerical data
Urban Population
/ statistics & numerical data
abortion
health policy
implementation
integrated knowledge translation
knowledge mobilization
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
20 04 2019
20 04 2019
Historique:
entrez:
22
4
2019
pubmed:
22
4
2019
medline:
18
4
2020
Statut:
epublish
Résumé
In January 2017, mifepristone-induced medical abortion was made available in Canada. In this study, we will seek to (1) understand facilitators and barriers to the implementation of mifepristone across Canada, (2) assess the impact of a 'community of practice' clinical and health service support platform and (3) engage in and assess the impact of integrated knowledge translation (iKT) activities aimed to improve health policy, systems and service delivery issues to enhance patient access to mifepristone. This prospective mixed-methods implementation study will involve a national sample of physicians and pharmacists recruited via an online training programme, professional networks and a purpose-built community of practice website. Surveys that explore constructs related to diffusion of innovation and Godin's behaviour change frameworks will be conducted at baseline and at 6 months, and qualitative data will be collected from electronic interactions on the website. Survey participants and a purposeful sample of decision-makers will be invited to participate in in-depth interviews. Descriptive analyses will be conducted for quantitative data. Thematic analysis guided by the theoretical frameworks will guide interpretation of qualitative data. We will conduct and assess iKT activities involving Canada's leading health system and health professional leaders, including evidence briefs, Geographical Information System (GIS)maps, face-to-face meetings and regular electronic exchanges. Findings will contribute to understanding the mechanisms of iKT relationships and activities that have a meaningful effect on uptake of evidence into policy and practice. Ethical approval was received from the University of British Columbia Children's and Women's Hospital Ethics Review Board (H16-01006). Full publication of the work will be sought in an international peer-reviewed journal. Findings will be disseminated to research participants through newsletters and media interviews, and to policy-makers through invited evidence briefs and face-to-face presentations.
Identifiants
pubmed: 31005943
pii: bmjopen-2018-028443
doi: 10.1136/bmjopen-2018-028443
pmc: PMC6500320
doi:
Substances chimiques
Abortifacient Agents, Steroidal
0
Mifepristone
320T6RNW1F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028443Subventions
Organisme : CIHR
ID : PHE148161
Pays : Canada
Organisme : CIHR
ID : CPP-329455-107837
Pays : Canada
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Cochrane Database Syst Rev. 2015 Jul 27;(7):CD011242
pubmed: 26214844
Implement Sci. 2011 Jun 06;6:59
pubmed: 21645381
Can Fam Physician. 2016 Apr;62(4):e201-e208
pubmed: 28192275
Implement Sci. 2008 Jul 16;3:36
pubmed: 18631386
Aust N Z J Obstet Gynaecol. 2016 Dec;56(6):648-654
pubmed: 27440477
PLoS One. 2013 Jun 28;8(6):e67070
pubmed: 23840588
Cochrane Database Syst Rev. 2004;(2):CD002855
pubmed: 15106180
Contraception. 2012 Feb;85(2):185-91
pubmed: 22036474
PLoS One. 2014 Mar 18;9(3):e91013
pubmed: 24643173
Obstet Gynecol. 1999 Apr;93(4):576-80
pubmed: 10214836
Healthc Policy. 2015 Feb;10(3):48-63
pubmed: 25947033
Obstet Gynecol. 2004 Apr;103(4):729-37
pubmed: 15051566
Nebr Symp Motiv. 1980;27:195-259
pubmed: 7242748
Contraception. 2015 Sep;92(3):186-9
pubmed: 26096369
Am J Public Health. 2013 Apr;103(4):585-9
pubmed: 23409915
N Engl J Med. 2017 Feb 23;376(8):790-794
pubmed: 28225670
Lancet. 2015 Feb 21;385(9969):698-704
pubmed: 25468164
Implement Sci. 2013 May 16;8:52
pubmed: 23680355
Acta Obstet Gynecol Scand. 2014 Jul;93(7):647-53
pubmed: 24766569
Health Care Anal. 2010 Mar;18(1):17-34
pubmed: 18821017
Int J Nurs Pract. 2011 Jun;17(3):315-21
pubmed: 21605273
Contraception. 2013 Sep;88(3):350-63
pubmed: 23261233
Pilot Feasibility Stud. 2019 Nov 08;5:126
pubmed: 31720004
Implement Sci. 2016 Mar 17;11:38
pubmed: 26988000
Implement Sci. 2018 Feb 02;13(1):22
pubmed: 29394932
Res Nurs Health. 1995 Apr;18(2):179-83
pubmed: 7899572
Implement Sci. 2009 Mar 01;4:11
pubmed: 19250556
J Obstet Gynaecol Can. 2007 Aug;29(8):640-7
pubmed: 17714617
BMJ. 2017 Mar 6;356:i6795
pubmed: 28264797
N Engl J Med. 2011 Dec 8;365(23):2198-204
pubmed: 22150038
CMAJ. 2010 Feb 9;182(2):E78-84
pubmed: 19969563
Perspect Sex Reprod Health. 2002 May-Jun;34(3):154-61
pubmed: 12137129
BJOG. 2015 Mar;122(4):510-7
pubmed: 25040643
Contraception. 2015 Sep;92(3):177-8
pubmed: 26142617
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
Can Fam Physician. 2016 Apr;62(4):e209-e217
pubmed: 28192276
Worldviews Evid Based Nurs. 2012 Dec;9(4):210-20
pubmed: 22672620
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
Reprod Health Matters. 2015 Nov;23(46):169-76
pubmed: 26719008
Contraception. 2015 Nov;92(5):422-38
pubmed: 26238336
CMAJ. 2014 Jan 7;186(1):13-4
pubmed: 24277708
Implement Sci. 2012 Jul 03;7:59
pubmed: 22759451
PLoS One. 2013 Jun 28;8(6):e67023
pubmed: 23840578